Clinical Research, The National Cancer Institute, Ciudad de Mexico 14080, Mexico.
Basic Research Division, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Int J Mol Sci. 2024 Aug 28;25(17):9328. doi: 10.3390/ijms25179328.
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy worldwide. Molecular classifications have tried to improve cure rates. We prospectively examined and correlated the mutational landscape with the clinical features and outcomes of 185 Mexican patients (median age 59.3 years, 50% women) with newly diagnosed DLBCL. A customized panel of 79 genes was designed, based on previous international series. Most patients had ECOG performance status (PS) < 2 (69.2%), advanced-stage disease (72.4%), germinal-center phenotype (68.1%), and double-hit lymphomas (14.1%). One hundred and ten (59.5%) patients had at least one gene with driver mutations. The most common mutated genes were as follows: , , , , and . The median follow-up was 42 months, and the 5-year relapse-free survival (RFS) and overall survival (OS) rates were 70% and 72%, respectively. In the multivariate analysis, both age > 50 years and ECOG PS > 2 were significantly associated with a worse OS. Our investigation did not reveal any discernible correlation between the presence of a specific mutation and survival. In conclusion, using a customized panel, we characterized the mutational landscape of a large cohort of Mexican DLBCL patients. These results need to be confirmed in further studies.
弥漫性大 B 细胞淋巴瘤(DLBCL)是全球最常见的 B 细胞恶性肿瘤。分子分类试图提高治愈率。我们前瞻性地检查并关联了 185 名新诊断为 DLBCL 的墨西哥患者(中位年龄 59.3 岁,50%为女性)的突变景观与临床特征和结局。基于先前的国际系列研究,我们设计了一个定制的 79 个基因的面板。大多数患者的 ECOG 表现状态(PS)<2(69.2%),疾病处于晚期(72.4%),具有生发中心表型(68.1%)和双打击淋巴瘤(14.1%)。110 名(59.5%)患者至少有一种具有驱动突变的基因。最常见的突变基因如下: 、 、 、 、 。中位随访时间为 42 个月,5 年无复发生存率(RFS)和总生存率(OS)分别为 70%和 72%。在多变量分析中,年龄>50 岁和 ECOG PS>2 均与 OS 不良显著相关。我们的研究没有发现特定突变的存在与生存之间存在任何明显的相关性。总之,使用定制的面板,我们描述了一个大型墨西哥 DLBCL 患者队列的突变景观。这些结果需要在进一步的研究中得到证实。